|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Also, IFN-β suppresses tumor growth by the induction of apoptotic process.
|
31512776 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibition of SUV39H1 leads to transcriptional activation of these genes, especially RIG-I, followed by increased IFNβ and λ<sub>1</sub> production after poly(dA:dT) or RIG-I agonist M8 transfection, Collectively, our findings provide new evidence that the E7 oncoprotein plays a central role in dampening host innate immunity and raise the possibility that targeting the downstream effector SUV39H1 or the RIG-I pathway may be a viable strategy to treat viral and neoplastic disease.<b>IMPORTANCE</b> High-risk HPVs are major viral human carcinogens responsible for approximately 5% of all human cancers.
|
31776268 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The rates of tumor cell apoptosis in the IFN-β and IFN-β-MSCs groups were significantly higher than those in the MSCs-lentivirus and MSCs groups.
|
30683475 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Role of interleukin-24 in the tumor-suppressive effects of interferon-β on melanoma.
|
31070806 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We also administered interferon beta-transduced mMSCs (mMSCs-IFN-β) to MYCN-TgM i.p. and measured the concentration of IFN-β in the tumor and organs by an enzyme-linked immunosorbent assay (ELISA).
|
31627888 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Distinct Roles of Direct Transduction Versus Exposure to the Tumor Secretome on Murine Endothelial Cells After Melanoma Gene Therapy with Interferon-β and p19Arf.
|
30848981 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, the therapeutic use of IFN-β to treat OSM-driven tumors significantly suppresses tumor growth.
|
31036052 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These results suggest that serum deprivation during the culture of 40K-ASCs or during the washing step of 5K-ASCs can induce IFN-β and/or TRAIL expression, ultimately leading to the tumor suppression capability of ASCs.
|
30393160 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IFN-β inhibits multiple tumor cell growth in vitro.
|
31358054 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFNβ-Driven Antitumor Immunity.
|
31431457 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A phase III trial of adjuvant therapy with locoregional interferon (IFN)-β versus surgery alone is ongoing in Japan (JCOG1309, J-FERON), in which IFN-β is injected directly into the site of the primary tumor postoperatively, so that it would be drained through the untreated lymphatic route to the regional node basin.
|
30675668 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Type I interferons (IFNα and IFNβ) directly regulate transcription of >100 downstream genes, which results in a myriad of direct (on cancer cells) and indirect (through immune effector cells and vasculature) effects on the tumour.
|
30679806 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Combination ruxolitinib and VSV-IFNβ therapy resulted in a trend toward improved survival of mice without substantially effecting PDL-1 levels or levels of immune infiltration into the tumor.
|
30622322 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Future studies aim to improve methods to target delivery of IFN-β to tumors, to maximize therapeutic efficacy while minimizing systemic side effects.
|
29750542 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We observed that tumors treated with PD-1/PD-L1 blocking antibodies develop resistance through the upregulation of CD38, which is induced by all-trans retinoic acid and IFNβ in the tumor microenvironment.
|
30012853 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We identified inactivating somatic mutations in the NF1 gene in three of six tumors; the only other gene altered in more than one tumor was IFNB1.
|
29849115 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We also created a highly secretable variant of immune cytokine IFNβ to enhance its release from engineered mouse mesenchymal stem cells (MSC-IFNβ) and assessed whether surgical resection of intracranial GBM tumor significantly enhanced the antitumor efficacy of targeted on-site delivery of encapsulated MSC-IFNβ.<b>Results:</b> We show that tumor debulking results in substantial reduction of myeloid-derived suppressor cells (MDSC) and simultaneous recruitment of CD4/CD8 T cells.
|
28912136 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IFN-β gene therapy was effective in suppressing tumor growth in the liver but not effective for those in the lung and kidneys.
|
28337378 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Oncolytic VSV engineered to express interferon-beta (IFNβ) and the sodium iodide symporter (NIS), VSV-IFNβ-NIS, has been shown to be a potent new therapeutic agent inducing rapid and durable tumor remission following systemic therapy in preclinical mouse models.
|
28514874 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD can convert a prodrug, 5-fluorocytosine (5-FC), to active 5-fluorouracil, which inhibits tumor growth through the inhibition of DNA synthesis,while IFN-β also strongly inhibits tumor growth by inducing the apoptotic process.
|
27188205 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
While the addition of checkpoint inhibitors to VSV-IFNβ generated robust tumor growth inhibition, it resulted in no increase in viral replication, transgene expression, or immunophenotypic changes beyond treatment with VSV-IFNβ alone.
|
28578991 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Next, we screened five AAV-IFN-β vectors with different promoters to drive safe expression of mouse IFN-β in the brain in the context of syngeneic GL261 tumors.
|
28098415 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Stimulator of interferon genes (STING) signaling induces IFNβ production by intratumoral dendritic cells (DC), driving T-cell priming and recruitment into the tumor microenvironment (TME).
|
28483787 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The combination of bleomycin with suicide or interferon-β gene transfer is able to efficiently eliminate human melanoma tumor initiating cells.
|
27399807 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we have identified the role of host type I IFNs, cell populations that are sources of IFN-β in the tumor microenvironment, and other host requirements for tumor control in this model.
|
26880763 |
2016 |